| Names | |
|---|---|
| Preferred IUPAC name | (4aR,10,10aS)-6-methoxy-11-methyl-1,2,3,4,4a,9,10,10a-octahydro-6H-10,4a-iminophenanthrene hydrobromide |
| Other names | DXM Dextromethorphan HBr Dextromethorphan Methyl Dextromethorphan DXM HBr |
| Pronunciation | /ˌdɛkstrəʊˌmɛˈθɔːrfæn haɪˈdrɒˌbrəʊmaɪd/ |
| Identifiers | |
| CAS Number | 125-69-3 |
| 3D model (JSmol) | `3D model (JSmol)` string of **Dextromethorphan Hydrobromide**: ``` CC1(C2CCC(C1C3=CC=CC=C3)(C2)OC)N.CBr ``` |
| Beilstein Reference | 1364806 |
| ChEBI | CHEBI:4476 |
| ChEMBL | CHEMBL946 |
| ChemSpider | 12798 |
| DrugBank | DB00514 |
| ECHA InfoCard | 03b298ce-411e-414d-a05a-35d5e6fa2530 |
| EC Number | 211-095-0 |
| Gmelin Reference | 109022 |
| KEGG | D08143 |
| MeSH | D009042 |
| PubChem CID | 5360696 |
| RTECS number | QI0525000 |
| UNII | QNK0VPB41O |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID0022150 |
| Properties | |
| Chemical formula | C18H25NO·HBr |
| Molar mass | 370.33 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 0.5 g/cm³ |
| Solubility in water | Very soluble in water |
| log P | 2.7 |
| Acidity (pKa) | 8.3 |
| Basicity (pKb) | 8.3 |
| Magnetic susceptibility (χ) | -8.6e-6 cm³/mol |
| Dipole moment | 2.7492 D |
| Thermochemistry | |
| Std enthalpy of formation (ΔfH⦵298) | -340.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4994 kJ/mol |
| Pharmacology | |
| ATC code | R05DA09 |
| Hazards | |
| Main hazards | Harmful if swallowed. May cause respiratory depression, dizziness, or drowsiness. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Store at temperature not exceeding 30°C, protected from light and moisture. Keep out of reach of children. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | Flash point: 233.3°C |
| Autoignition temperature | 280°C |
| Explosive limits | Non-explosive |
| Lethal dose or concentration | LD₅₀ (oral, rat): 170 mg/kg |
| LD50 (median dose) | 120 mg/kg (rat, oral) |
| NIOSH | WX6R8Q11DR |
| PEL (Permissible) | 10 mg/m³ |
| REL (Recommended) | 30 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Levomethorphan Racemethorphan Dextrorphan 3-Methoxymorphinan Codeine Morphine |
| Aspect | Description |
|---|---|
| Product Name & IUPAC Name |
Dextromethorphan Hydrobromide (IUPAC: (+)-3-Methoxy-17-methyl-9α,13α,14α-morphinan hydrobromide monohydrate) |
| Chemical Formula | C18H25NO•HBr•H2O |
| Synonyms & Trade Names | DXM HBr, Dextromethorphan HBr, Dextromethorphan Hydrobromide Monohydrate |
| HS Code & Customs Classification |
2939.00: Alkaloids and derivatives Specific sub-classification applied according to end-use and origin requirements. For pharmaceutical grades, further division may depend on regulatory region or finished dosage preparation. |
Dextromethorphan Hydrobromide manufacturing focuses on consistent yield, operational reproducibility, and minimizing sources of variability during synthesis and subsequent crystallization. Raw material quality remains a primary driver for reaction selectivity. In production, hydrobromide formation follows strict pH and temperature management to control polymorphic output, affecting filterability and downstream handling. Hydrate form monitoring is critical as moisture pickup after drying directly affects bulk density, flow behavior, and compounding steps by dosage manufacturers.
Material specifications reflect intended use: oral pharmaceutical, veterinary, or intermediate. Pharmaceutical grades restrict process contaminants tightly, particularly residual solvents, unreacted amines, and morphinan-related impurities. The impurity profile is variable based on reaction path and mother liquor reuse. Any adjustment in crystallization kinetics or solvent system changes impurity carry-over and hydrate distribution, which has direct consequences for tableting properties and storage stability at the drug product stage.
Customs handling practices diverge by country and application; as a controlled active pharmaceutical ingredient, routing through customs often involves documentation on intended medicinal end-use, with different requirements for import as bulk API versus finished formulation. Manufacturer registration numbers may be needed for customs declarations, and the HS code assignment can require supporting purity and specification documentation.
Dextromethorphan hydrobromide typically presents as a white to off-white crystalline powder in IP, BP, USP, and industrial grades, reflecting tight control of crystallization conditions and purification steps. Faint odor and a bitter taste are typically reported, although these are imperceptible in pharmaceutical and food additive applications due to low use levels. Melting points for bulk lots are grade-dependent, usually confirmed during batch release for pharmaceutical grades to validate lot consistency. Boiling point data is less relevant given decomposition prior to boiling under atmospheric conditions. Notable discrepancies in powder color may indicate trace impurities or process variation, prompting detailed lot investigation.
Stability of dextromethorphan hydrobromide holds under cool, dry, and controlled environmental storage. Exposures to excessive moisture, oxidizers, or direct light degrade product integrity. Age-related yellowing or clumping signals hydrolytic or oxidative decomposition. General reactivity is low under controlled storage, but presence of acid, base, or oxidants in downstream formulations may promote degradation.
Solubility in water rises with temperature and agitation, but highly concentrated solutions tend to form upon dissolution in neutral or mildly acidic pH. Poor dissolution or haze points to inappropriate pH or significant excipient load. Alcohol readily dissolves the product, expanding formulation options for syrups and suspensions. Final solution quality is solution pH and batch impurity dependent; intervention may be required for high-purity injectable or analytical applications.
Specification tables distinguish pharmaceutical from technical grades. Typical targets include assay percentage, moisture content, specific optical rotation, residual solvents, and heavy metals. Impurity boundaries are set tighter for injectable, oral, or pediatric applications than for excipient or technical use. Release thresholds shift based on customer registration, local pharmacopoeial mandates, and product end use.
Impurities mainly arise from raw material quality, incomplete reaction, carryover from mother liquor, and processing/handling. Main impurities are residual starting material, side products from methylation or bromination, and solvent residues. Limits follow targeted ICH, USP, EP, or JP standards when pharmaceutical grade is ordered; technical grade specs are broader. Testing by HPLC, GC, or titration validates in-process control, but full impurity profiling is batch-release dependent.
Testing follows pharmacopeial or in-house monographs designed according to the grade. Activity (assay), clarity, identification, impurity checks, and water content get priority in QC protocol. Analytical techniques include HPLC for assay/impurity, titration for water/acid/base-sensitive tests, and refractometry for optical rotation. Each batch’s analytical method is logged in the documentation retained for regulatory audit and customer review.
Selection focuses on the purity and the traceability of starting alkaloids (often synthetic or naturally derived), methylating agents, and hydrobromic acid. Sourcing for pharmaceutical grade mandates full vendor qualification, impurity cross-checking, and routine supplier audits. Local market supply can alter the synthesis pathway due to availability and regulatory constraints concerning precursor import and storage.
Most manufacturers utilize a methylation step under controlled base and solvent conditions, reacting a precursor alkaloid to form dextromethorphan base, followed by acidification with hydrobromic acid to yield the hydrobromide salt. The reaction sequence, including pH buffer, order of addition, temperature, and time, impacts yield and impurity generation. Grade-specific requirements modify details: injectable and pediatric APIs demand higher monitoring and often double or triple recrystallization.
Critical controls include temperature, pH, rate of acid addition, and solvent quality. Solvent purity and recycling status can change the impurity profile and pigment formation. Crystallization temperature, seed amount, and filtration timing affect bulk density and particle habits. Process water, air handling (HEPA filtration), and anti-static procedures are prioritized to reduce batch-to-batch variability.
Quality control checks define lot acceptability and final batch release. Stringent monitoring covers assay, major/minor impurity breakdown, water content, and appearance. Batch release standards differ by region and contract terms; customer-specific monographs sometimes override plant internal specs. Out-of-spec results trigger hold, investigation, and often full batch trace to root cause.
The molecule displays stable resistance to hydrolysis under normal storage, but aromatic N-methyl dissociation or demethylation is feasible with strong acids/bases and oxidants. In laboratory settings, N-demethylation or further bromide exchange are recognized conversion routes for research or derivative synthesis.
Process temperatures, solvents, and catalytic conditions for derivatization depend on downstream requirements. Higher solubility solvents and inert atmosphere techniques may be applied for sensitive derivatives. Bromide-to-chloride or sulfate salt exchanges utilize controlled acid addition or ion-exchange resins.
The most important derivatives include N-demethylated or O-alkylated analogues, often explored for research or patent extension. Downstream integration depends on reaction cleanliness and removal of residual catalyst, bromide, and processed solvent impurities.
Cool, low-humidity storage is prioritized to suppress hydrolytic decomposition and agglomeration. Light avoidance helps prevent color shift linked to minor photo-oxidative processes. Bulk lots are packed with desiccant and in airtight containers. Inert gas blanketing is not standard for routine bulk shipments, but small-scale critical grades occasionally receive nitrogen blanketing.
HDPE and polypropylene containers dominate, chosen for chemical resistance and extractable containment. Glass may be used for controlled samples or analytical standards. Packaging is matched to customer fill line and handling requirements; bulk APIs require lining to prevent abrasion and particle attrition.
Shelf life is grade-specific, influenced by storage, purity, and packaging. Typical values depend on label specification and customer registration; degradation is tracked by trend data on assay, appearance, water content, and off-odor. Color change, agglomeration, or decrease in assay signals product deterioration. Accelerated stability data supports actual expiry.
Dextromethorphan hydrobromide generally falls under "harmful if swallowed" and "skin/eye irritant" categories for bulk chemical. Both technical and API grades are labelled as such. Risk and safety phrases matter during handling and are based on international and local GHS classifications as per batch documentation.
Toxicity and exposure thresholds depend on occupational exposure setting and product grade. Manufacturing lines implement dust extraction, PPE, and closed transfer lines for bulk handling. Large-scale exposure risks focus on inhalation and accidental ingestion, so manufacturing training covers spill/emergency protocols. Specific toxicity data references current published values in the public domain and customer MSDS requests. Automated and semi-automated environments offer the best exposure limitation; smaller or older plants rely on manual transfer with higher engineering control demands.
From the plant floor, production capacity for Dextromethorphan Hydrobromide scales with the output and configuration of reaction lines, solvent recovery units, and purification columns. Reactor throughput and campaign scheduling directly influence batch availability. Equipment maintenance cycles, utility supply, and raw material lead times create bottlenecks when demand surges or infrastructure faces constraints. Advanced orders drive planning: the more predictable the rolling forecast from buyers, the greater the output reliability. Stock levels fluctuate by production scale and logistics cycle—periodic plant shutdowns, solvent or reagent disruptions, and regulatory inspections can cut available inventory in the short term.
Minimum order quantities (MOQ) stem from upstream solvent charge size, filtration equipment, and warehousing logistics. For high-purity pharmaceutical grade, cleaning validation protocols and segregated production dictate partial batch fulfilment policy. Standard lead time hinges on both current campaign status and quality release testing: non-pharma grades typically process faster through release, while cGMP-compliant API batches require full analytical review and documentation. Unscheduled demand or rush orders often face expedited fees, while routine contracts allow level-loading of the production cycle.
Bulk packaging formats include fiber drums with PE liners or high-density PE drums. Smaller batches for R&D or specialty pharma needs ship in HDPE bottles or glass containers. Packaging selection depends on grade and regulatory market: pharma customers require tamper-evident, traceable, and often nitrogen-flushed primary containers. Industrial customers focus on volumetric efficiency and protection against hygroscopicity. Incompatibility with certain plastics and moisture sensitivity drive internal packaging checks before dispatch.
Shipment routes depend on global regulatory approvals, import permit timelines, and air/sea freight conditions. Most exports comply with Incoterms—FOB, CIF, and EXW are commonly negotiated. Many buyers require the latest regulatory documentation in their local language, often embedded in the shipping paperwork. Payment terms range from standard prepayment to net-30/60 days for large-volume, repeat customers with established credit. Delays sometimes arise from customs classification reviews or end-use verification, especially in controlled substance regimes.
The cost foundation splits between synthetic organic intermediates (such as morphinan derivatives), specialty reagents, solvent recovery, and multi-stage purification. Upstream factors like crude oil pricing and supply chain shocks affect the cost of primary solvents and minor catalyst inputs. Regulatory shifts on controlled precursor sourcing sometimes add compliance surcharges. Purification and analytical release represent non-trivial cost blocks, especially for pharmaceutical and injectable grades—each batch run incurs additional labor, documentation, and QA/QC overhead.
Price stratification reflects specification bands: pharmaceutical API, excipient grade, or technical grade. High-purity (≥99.5% HPLC) for regulated markets commands a premium for extensive documentation and cGMP compliance overhead. Technical grade typically contains slightly higher organic/inorganic residues, acceptable for non-medicinal use, and ships with basic certificate of analysis. Packaging in certified, tamper-evident pharma drums or unit-dose containers also adds cost relative to industrial bulk formats. Regional GMP/DMF registration and Kosher/Halal or other third-party certifications represent additional premium sources.
Feedstock supply interruptions, environmental policy changes, anti-dumping tariffs, and local production quotas often alter input pricing. Environmental regulations on solvent emissions and waste management in key producer regions impose compliance upgrades, sometimes leading to sudden shutdowns or “black swan” escalations in procurement. Secondary impacts arise from shipping costs, port congestion, and foreign exchange volatility between USD, RMB, INR, and EUR.
Dextromethorphan demand follows cold/flu seasonal patterns in the US, EU, and Japan, with anti-tussive usage peaking in the winter months. Emerging market growth, particularly in India and Southeast Asia, draws on both locally produced and imported stock, sometimes creating asymmetric inventory spikes. China’s domestic production scale plays a stabilizing role during normal operations but can amplify volatility during regulatory crackdowns or feedstock shortages. Global output distribution remains top-heavy: a handful of manufacturers account for bulk of regulated, high-purity output, while regional players service commodity and bulk grades.
US and EU consumption emphasizes compliance, traceability, and QA/QC documentation, which limits supply flexibility when regulatory rules tighten or DMF submissions require updates. Japan’s quality standards and batch recall readiness drive demand for premium grades and extensive stability data. India’s upstream manufacturing expansion faces hurdles in regulatory harmonization and input cost pressures; both local and export supply see price responsiveness to these shifts. In China, government oversight and controlled precursor regulation can rapidly tilt availability, especially following new anti-diversion rounds or national standard updates.
Forward pricing models draw from feedstock futures, policy trend analysis in major economies, and historical volatility data from tracked contract settlements. Analysts expect regulatory-driven cost inflation to persist, with pharma-grade price floors rising along with environmental compliance costs in China and India. Energy price volatility and logistics costs—fueled by shipping disruptions—remain key unknowns. Demand is set to grow modestly in volume, but price compression is unlikely for high-purity cGMP grades before 2026. Technical and bulk grade markets may face more cyclic pricing as regional overcapacity shifts bargaining power toward buyers in lower-regulated markets.
Supply chain interruptions in China due to periodic environmental audits, along with changing precursor import-export tariffs, force suppliers to reassess buffer stock strategies. Downstream reformulation trends, such as the push toward multi-API cough and cold medicines, increase the importance of impurity profiling data and customer technical support during supply transitions.
Recent cGMP updates in the EU and US have tightened requirements for traceability, batch release testing, and impurity limit validation. India’s export certification process recently saw updates in documentation standards, especially for regulated market shipments. The trend points toward expanding analytical support and longer review timelines for pharmaceutical grade supplies.
Production teams enhance supply chain resilience through diversification of solvent suppliers, close monitoring of environmental policy changes, and proactive communication with raw material vendors. Quality control adjusts in-process checkpoints to flag impurity trends linked to input variability. Logistics teams coordinate secondary shipping routes and dual-port shipping solutions to hedge against port congestion and regulatory action in core supply node economies. Customer-facing teams invest in digital documentation tools for real-time batch data and expedited certification support, enabling faster resolutions of customs or regulatory queries.
Dextromethorphan Hydrobromide enters multiple segments where controlled quality determines downstream performance and compliance. The backbone of its demand lies in pharmaceutical formulation, chiefly as a cough suppressant, with growing attention from analytical, veterinary, and research sectors. Each downstream market presents distinct technical demands, causing grade selection to turn on much more than nominal purity claims.
Pharmaceutical grade finds usage in over-the-counter solid and liquid dosage forms. Veterinary formulations rely on consistent batch reproducibility and defined impurity windows aligned to animal health regulations. Analytical applications, typically in reference standards or quality control labs, emphasize trace impurity knowledge and detailed assay reporting. Research and development contexts in pharmaceutical labs examine intermediate specification grades to match development budgets and project timelines.
| Application Field | Typical Grade | Key Considerations |
|---|---|---|
| Pharmaceutical Formulation (Human) | Pharma Grade (USP/EP/JP, or customer-specific) | Impurity profiles, residual solvents, assay values, microbiological control, batch traceability |
| Veterinary Formulation | Veterinary Grade or Pharma Grade | Consistent impurity thresholds, reproducibility, regulatory alignment to veterinary limits |
| Analytical/Reference Standard | High-Purity/Certified Reference Material | Traceability, low-level impurities, documentation, COA support |
| Pharmaceutical R&D | Development Grade | Flexible impurity limits, batch-to-batch variability allowance for early study use |
Assay and impurity values carry the most weight. In pharmaceutical production, controlled assay (usually above 98.0% by region or monograph) and suppression of specific impurities (such as dextrorphan, levorphanol, and solvents) underpin both compliance and formulation reliability. Details such as total impurity content, water content, and residual solvents shift by monograph (USP, PhEur, JP, etc.), and the manufacturer monitors these as part of release. Veterinary applications tolerate slightly more variability in non-critical impurity bands, but demand controlled heavy metal and solvent residues. Analytical uses demand the narrowest windows, with detailed impurity breakdown and documentation, since trace detection relies on statistical purity and certificate-backed traceability. R&D often trades the strictest thresholds for available, consistent, and documented material without the full cost of pharma release testing.
The target use determines the minimum documentation and specification scope. For regulated human use, only full-compliance pharmaceutical grades satisfy ethical or legal checks. Research and non-clinical study use may justify intermediate specs to balance budget and speed.
Choice of product release standard pivots on destination market and formulation type. Regulations set by FDA, EMA, or national authorities govern pharmaceutical and veterinary material, influencing allowable impurities, documentation, and source traceability. Direct reference to the latest pharmacopoeia and importing region requirements guides final grade confirmation. Inquiries from formulation teams should match both registration region and dosing route.
Grades differ in impurity content, moisture, and batch-to-batch control. Where impurity peaks or assay deviation impact formulation or analysis results, request detailed impurity profiling and batch history. For tight dose formulations or analytical applications, specify allowable solvent residues, heavy metal limits, and microbial specs based on internal formulation or analysis sensitivity.
Large-scale manufacturing and development programs often create trade-offs between price and grade strictness. Requesting full pharmaceutical release for pilot studies or low-dose research may prove unnecessary. Align grade and pack size to project phase and regulatory checkpoints, as well as to batch sample needs for validation, especially if using the material in separate global regions or with evolving quality standards.
Before committing to scale supply, run in-house validation or third-party analysis on a manufacturer-provided sample. Analytical performance, physical characteristics (such as bulk density for tablet blending), and impurity tables offer real-world confirmation beyond the certificate of analysis. Feedback after trial use feeds back into subsequent batch matching or order tailoring, particularly in pharma and veterinary supply chains where post-purchase rework or rejection is not feasible.
In the production of Dextromethorphan Hydrobromide, maintaining traceable, documented quality management is foundational. Our facility operates under an established quality assurance framework tailored to both pharmaceutical and industrial grade requirements. Audits from recognized international certification bodies validate whether relevant GMP, ISO 9001, or additional regulatory standards are being implemented. Internal audits by our own compliance team target manufacturing process consistency, focusing on the critical step controls that most influence grade and purity outcomes. Specific stages, including raw material verification, crystallization, and end purification, sit within the audit scope to address risk points for cross-contamination or process drift.
Certifications relevant to Dextromethorphan Hydrobromide rely on end-use requirements and target geography. Regulatory filings, such as Drug Master Files (DMFs) or written confirmations, support pharmaceutical market entry in regulated regions. Internal quality release is batch-based, with audit trails logging both in-process and final data, aligned with requirements set by customers or specific pharmacopeia. Food or veterinary grade demands invoke supplementary controls around input purity and residual solvent monitoring.
Release documentation for Dextromethorphan Hydrobromide includes Certificates of Analysis and production batch records, supported by analytical test reports generated via validated methods. Typical parameters include identity confirmation, assay, key impurity profiling, moisture determination, and, depending on region, elemental or residual solvent content. Document handover adapts to customer QA needs, including customizable specification sheets and regulatory dossiers. Data collection is digitalized, allowing batch linkage for any post-delivery investigation or recall protocols.
Managing supply reliability for Dextromethorphan Hydrobromide depends directly on the process’s core production capacity and production scheduling flexibility. We structure our material pipeline and workforce allocation to handle forecasted and surge market demands across pharmaceutical and industrial grades. Advanced production planning applications enable us to execute priority scheduling for urgent or mission-critical projects, minimizing lead times subject to available raw material volumes and running changeover logistics efficiently.
Our annual output capability for Dextromethorphan Hydrobromide adapts to seasonal and cyclical market conditions. Output stability traces back to dual-source supply of key precursors, established partnership with logistics firms, and a quality-driven batch validation logic that filters unsuitable outputs prior to customer notification. Capacity commitments are set according to historical offtake patterns and can be formally reserved based on strategic cooperation agreements.
Sample provision for Dextromethorphan Hydrobromide follows a defined, traceable protocol. Customers submit technical and compliance requirements. We evaluate the grade, specification, and intended use to determine appropriate sampling from validated inventory. Laboratory control samples are drawn as per documented SOPs, with chain-of-custody maintained up to dispatch. Corresponding batch documentation, including analysis reports, support traceability. For clients requiring non-standard evaluations or method transfers, additional coordination between our technical and regulatory teams can be initiated.
Adaptable cooperation models recognize the changing needs of formulators, contract manufacturers, and direct end-users. Volume-based pricing, forward contract arrangements, and contingency reserves enable risk-sharing approaches for strategic partners. For customers with variable forecast reliability or dynamic production cycles, we provide options for quarterly production scheduling, advance stock holding, and periodic re-qualification sampling. Collaborative development of specification targets and customized release criteria underpins value for both novel and established applications. We maintain readiness for validation support or compliance documentation gap-closure, reducing timelines for regulatory registration or internal approval.
In-house technical teams are prioritizing synthesis process refinement and impurity profile control for Dextromethorphan Hydrobromide to anticipate both regulatory and pharmacopoeial updates. Formulators in the pharma sector frequently consult on polymorphic control and residual solvent thresholds tailored to specific regional filings. There is a trend toward evaluating side-streams and process intermediates to optimize yield and impurity isolation at pilot and commercial scales.
Beyond antitussive formulations, collaborative research with partners in the CNS pharmaceutical sector is observing early interest in neuroprotective and adjunctive applications at the molecule level. Semi-synthetic derivatives and prodrug investigations sometimes arise from customer-driven feasibility requests. These require support for extended stability and impurity monitoring over longer time profiles than legacy cough/cold product uses.
Common challenges involve batch-to-batch variability in optical purity and controlling reduction byproducts during synthesis. Production implements a closed-loop feedback system for in-process monitoring of critical quality attributes, especially for high-purity and injectable grades. Adoption of green oxidants and solvent recovery steps marks a shift from legacy routes, improving both safety and regulatory acceptance. Continuous-flow synthesis has gained technical validation for certain scale brackets, especially as customers seek shorter lead times with less solvent load.
Demand remains tied to both seasonal respiratory trends and expansion in regulatory filings for modified usage. The outlook for the next three to five years projects moderate volume growth, with innovation driven largely by regulatory tightening in key regions. Emerging producer geographies may require additional technical support around raw material sourcing and process revalidation, depending on local requirements.
Focus is intensifying on upgrading process automation and real-time analytics for impurity mapping and process deviations. Transitioning away from some traditional halogenated solvents aligns both with health, safety, and environmental priorities and with the requirements of international buyers. Dedicated process lines for high-purity and injectable uses now operate under separate specification and release streams to segregate cross-contamination risks.
Large-scale operations increasingly deploy solvent recovery and waste minimization as standard practice, reducing environmental footprint. The switch from batch to semi-continuous processing, especially for certain precursors, has lowered hazardous reagent consumption and increased yields. Raw material qualification assessments now routinely consider sustainability criteria alongside cost and availability to reduce supply chain vulnerabilities.
Manufacturing teams field requests for process adaptability and impurity troubleshooting at the lab and plant scale. Technical experts provide guidance on chromatographic and spectroscopic fingerprint analyses, particularly where customer regulatory documents require tailored study designs. Recommendations for in-house analytical method validation and reference standard selection derive from accumulated manufacturing experience.
Direct support for formulation scientists includes recommendations for the selection of grade and batch based on end-use, particularly where excipient-API compatibility or impurity profiles might affect finished product release. Batch samples and CoA documentation can be customized according to the intended regulatory filing region or downstream transformation requirements.
Post-delivery support covers extended retest studies and feedback on observed deviations during customer scale-up runs. The quality team remains available to investigate and resolve issues related to shipment, storage stability, and performance in line with customer-supplied feedback. Repeatability, traceability, and batch data archiving are maintained for all high-purity and specialty grades to facilitate regulatory inquiry responses and recalls if needed.
Operating our own synthesis facilities, we produce Dextromethorphan Hydrobromide for contract and bulk industrial buyers across multiple sectors. Our controlled site handles each step, from active ingredient reaction to final crystallization, with batch-to-batch data archived for traceability and regulatory reference. This direct stewardship of the production process gives business buyers predictable output and full process transparency.
Dextromethorphan Hydrobromide goes into both high-volume and specialty pharmaceutical manufacturing lines, including cough suppressant formulations, combination OTC preparations, and research scale-up. Besides human health, some clients formulate for veterinary applications or specialty R&D intermediates. Our manufacturing scale covers both campaign-based large orders for continuous granulation operations and flexible batches for pilot projects.
Consistency underpins industrial value. Our inline process analytics and controlled environments regulate moisture, particle size, and active content. Every lot passes HPLC and impurity profiling to match specifications. These steps support repeatable downstream blending without surprise out-of-specification results. Full QC reports ship with every consignment and retention samples stay on site for client reference.
We fill and seal Dextromethorphan Hydrobromide in high-barrier, tamper-evident containers from 1 kg to 250 kg. For larger buyers, palletized drums and secondary shrink-wrap reduce accidental exposure and shipping losses. Our logistics group arranges direct dispatch, customs pre-clearance, and regulatory document integration for export. Supply capacity scales for both just-in-time drop-shipment and planned multi-month rollouts.
Our technical support team works closely with scale-up engineers, formulation chemists, and regulatory teams in buyer organizations. Material safety files, analytical method validation, and process trouble-shooting come standard. Supporting clients through change control and process optimization sessions helps maintain stability in finished dose and intermediate manufacturing.
Direct access to source production allows buyers to manage risk and simplify supply chain audits. By holding full traceability and adjustment control at plant level, our facility reduces downstream regulatory delays for finished product release. Industrial buyers avoid the supply uncertainty found with aggregated or unknown-origin material, gaining control over both cost and specification consistency.
Business partners build their formulations and market commitments on reliable material flows. We maintain a firm commitment to manufacturing control, documented output, and long-term business continuity for pharmaceutical and industrial buyers. Every order delivers not just a chemical, but a foundation for stable production agreements and responsive technical partnership.
We manufacture Dextromethorphan Hydrobromide under close regulatory supervision, fully aligned with the latest editions of both USP and EP. Rigorous analytical work on every batch forms the cornerstone of our quality assurance. Assay and impurity limits are never treated as generic numbers—they define our operational discipline. Newer compendial standards have tightened controls, but with our process investment, we consistently meet and even surpass published limits.
According to the latest USP and EP standards, the accepted assay for Dextromethorphan Hydrobromide must land within the 98.0% to 102.0% range on anhydrous basis. Our production protocols consistently deliver material well within that interval. Our analytical method validation undergoes regular review, and recalibration of HPLC and titration apparatus supports data integrity. Deviation means automatic review by our quality head—with investigation running all the way to root cause before moving any batch forward.
Pharmacopeias push for exacting controls. Granular humidity checks take place in real time, and we store each lot under nitrogen or desiccant to minimize variance. No sample leaves our QC lab unless both the certificate of analysis and internal audit signoff on the final values. This approach keeps our outgoing lots both pharmacopeia-compliant and robust through downstream formulation.
Impurities attract even more scrutiny from regulatory inspectors, and for good reason. N-oxide, 3-methoxymorphinan, and related substances are closely monitored. Total impurities must stay below 1.0%, with individual uncontrolled impurities restricted to 0.1% or lower, per the most recent USP and EP monographs.
We invest in targeted controls at the synthesis and purification stages. There’s no shortcut to controlling mutagenic and process-related impurities; it’s routine for our analytical chemists to track trends and map possible emerging peaks over time. Our validated HPLC and mass spectrometry methods provide us with deep visibility, making sure that nitrosamine and genotoxic impurities remain undetectable batch after batch. Commitment to regular system suitability and impurity profiling means we can immediately intervene if our trend data suggest any out-of-spec creep.
Securing a tight impurity profile at scale never comes easy. Over-alkylation, incomplete hydrolysis, or solvent issues demand proactive process optimization rather than retroactive correction. Our response includes continuous cleaning validation, in-process checks at strategic intervals, and ongoing staff training.
Pilot lots serve as the proving ground for parameter changes before any full-scale adoption. Data logging, process control systems, and actionable SOPs ensure every operator, from technician to shift manager, understands exactly where risk can creep in. We keep a close eye on regulatory updates, feeding that information back into our yearly raw material supplier reviews and our own internal audits.
Meeting compendial assay and impurity thresholds reflects only part of our mission. We see the monograph as a baseline. Customer audits, market recalls, and patient expectations push us to exceed those numbers where feasible. Direct-from-source manufacturing means total transparency over origins, impurity evolution, and the rationale behind every COA figure. Customers relying on our Dextromethorphan Hydrobromide aren’t simply matching specs—they’re accessing the outcome of continuous process improvement, years of experience, and a direct relationship with the people designing and safeguarding the process from start to finish.
In the bulk chemical industry, MOQ and lead time can make or break production schedules and cost projections. As a direct manufacturer of Dextromethorphan Hydrobromide, transparency about our practices helps partners plan without surprises. No two factories operate identically, but our experience shows clear industry patterns driven primarily by raw material handling, batch process constraints, and logistics realities.
The actual minimum sets the floor for viable production. To maintain batch integrity and keep the quality system robust, our production process supports runs sized for either the pharmaceutical sector or industrial-scale buyers. For Dextromethorphan Hydrobromide, our MOQ has settled over the years at 25 kilograms per order. This amount reflects the minimal efficient batch yielding a consistent and validated result every time. Below this, yields become inconsistent and resource losses rise. Cost of packaging, testing, and documentation becomes disproportionate if broken into micro batches; small volumes strain both production and quality teams.
We do not entertain MOQ requests purely to meet shipping carton capacity. Instead, we support buyers looking to coordinate their supply chain in step with actual consumption and inventory policies. By sticking to this MOQ, we avoid having leftover sub-batches where uniformity can drift if storage is prolonged or containers opened repeatedly. The customer gets fresher material in every shipment.
As with most active pharmaceutical ingredients, lead time ties directly to several factors. We operate continuous campaign production during high-demand months, but must periodically clean lines and validate with fresh starting materials to ensure compliance with GMP. On a rolling production schedule, lead time for Dextromethorphan Hydrobromide bulk orders usually falls within four to six weeks from confirmation to shipment readiness. This window gives our technical team the time they need for full QC analytics by HPLC, microbial testing, and release certification. We will not sacrifice this window for quick-turn demands because regulatory compliance deserves priority over speed. Bulk buyers who work with us plan ahead and signal projected needs, securing their slots months in advance. This smooth scheduling reduces bottlenecks and balances ongoing production with scheduled maintenance outages.
Delays seldom happen but, if they do, causes trace straight back to force majeure on raw material shipments or unplanned regulatory site audits. Our procurement team qualifies primary and alternate sources for all inputs, building resilience into every campaign. Large-scale buyers also often face last-minute changes in demand forecasts and inventory targets at their end—our long-term customers benefit from transparent order tracking, forecast sharing, and direct access to plant managers who proactively communicate production statuses. Tight coordination allows us to flex volume across several orders if a batch run produces an overage. We can sometimes deliver earlier if slotting allows, but never compromise testing protocols for speed.
MOQ sets predictable expectations for both sides—our factory and our customers. Lead time reflects the real-world pace of compliance testing and batch release. Over-promising with substandard shortcuts cannot serve the best interests of our partners or the patients they ultimately serve. Decades of experience in Dextromethorphan Hydrobromide manufacturing guide every decision on these logistics, keeping long-term value and integrity in focus with every shipment.
Managing dextromethorphan hydrobromide production in today's tightly regulated chemical landscape means working closely with various export, import, and health authorities. We maintain active registration with relevant local and international agencies for the manufacture, handling, and sale of controlled substances. Our compliance does not stop with domestic regulation—our technical and logistics staff routinely evaluate legal frameworks involved with each shipment, particularly as dextromethorphan sits on many international controlled substance lists, including those under the UN Convention on Psychotropic Substances.
Every outgoing shipment receives oversight from our regulatory affairs unit. We prepare, verify, and issue documentation required for lawful cross-border movement—these papers typically include a certificate of analysis, manufacturing license, and an export certificate showing full traceability. Individual countries often impose their own documentation requirements. For example, shipments to the United States or members of the European Union may demand import permits, pre-shipment notifications, or additional attests from an authorized regulatory body.
Our team routinely supports customers as they apply for their import clearances. We help compile full country-of-origin details and batch numbers, provide analytical and quality documentation validated against pharmacopeial standards, and arrange legalization or consular legalization where local laws require it.
Inspection is part of daily business in this category. Our manufacturing site undergoes systematic internal compliance audits and prepared inspections by third parties and government regulators. Documented control of inputs and finished product batches allows for auditable records, which are critical for evidence in support of scheduled product status. All production and supply records are archived in compliance with international retention mandates and readily accessible for review by authorities.
Shipping dextromethorphan hydrobromide into regulated markets often poses unexpected challenges. Government agencies respond to evolving patterns in drug diversion by updating substance scheduling or documentation guidelines with little advance notice. We address this by investing in regulatory updates and frequent legal review. Our documentation process adapts to new classification or notification demands. Across many shipments, we've managed sudden requests for in-transit authorizations, country-specific shipment tracking, and new licensing document formats.
Direct and early engagement with authorities has proven the best path. Fast response times to compliance queries, a complete record of controlled shipments, and the ability to issue documentation traceable all the way back to the production batch have prevented customs holds and penalty risk for our customers.
As a direct manufacturer, we see ongoing changes in global narcotics and psychotropic substance control as a critical factor in supply reliability. We monitor updates through formal industry channels and partner with professional regulatory advisors to ensure our documentation matches the latest standards. This reduces supply interruptions, minimizes delay, and underlines a consistent approach to lawful trade of dextromethorphan hydrobromide.
For each shipment, our regulatory and logistics teams coordinate closely from point of production to global delivery, providing not only the product but also the correct, current documentation demanded by authorities. By working at the source, we can guarantee full compliance, batch-level traceability, and help partners navigate today’s international chemical regulations with confidence.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
